Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aurora SpineASAPF -3.78%39 Days Sales Outstanding is 64.89 as of Mar. 2026, which is 5% below its 10-year median of 68.01. GuruFocus rates ASAPF with a GF Score™ of 39/100 and a GF Value™ of $0.23 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 810 Medical Devices & Instruments companies, Aurora Spine ranks better than 51.85% on this metric.
Aurora Spine's average Accounts Receivable for the
three
months ended in Mar. 2026 was $3.15 Mil. Aurora Spine's Revenue for the
three
months ended in Mar. 2026 was $4.44 Mil.
Hence, Aurora Spine's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 64.89.
The historical rank and industry rank for Aurora Spine's Days Sales Outstanding or its related term are showing as below:
ASAPF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 49.5 Med: 68.01 Max: 94.12
Current: 64.11
During the past 13 years, Aurora Spine's highest Days Sales Outstanding was 94.12. The lowest was 49.50. And the median was 68.01.
ASAPF's Days Sales Outstanding is ranked better than 51.85% of 810
companies
in the Medical Devices & Instruments industry
Industry Median: 65.85
vs ASAPF: 64.11
Aurora Spine's Days Sales Outstanding
declined
from Mar. 2025 (66.84) to Mar. 2026 (64.89).
Aurora Spine (OTCPK:ASAPF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Aurora Spine Days Sales Outstanding Related Terms
Aurora Spine Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Aurora Spine's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASAPF vs ABT, SYK, MDT: Days Sales Outstanding Comparison
For the Medical Devices subindustry, Aurora Spine's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurora Spine Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aurora Spine's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Aurora Spine's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurora Spine (ASAPF) has a Days Sales Outstanding of 64.89 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Aurora Spine and its competitors. This is near median its historical median of 68.01. Over the past decade, Aurora Spine's Days Sales Outstanding has ranged from 49.50 to 94.12. According to the industry distribution chart, Aurora Spine ranks #390 out of 810 companies in the Medical Devices & Instruments industry, placing it in the top 48.1%.
Is Aurora Spine's Days Sales Outstanding too high?
Aurora Spine's current Days Sales Outstanding of 64.89 is near median its 10-year median of 68.01. Over the past 10 years, this metric has ranged from a low of 49.50 to a high of 94.12. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.85. Aurora Spine's value of 64.89 is 1.5% below this industry median. Based on the distribution chart, Aurora Spine ranks #390 out of 810 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Aurora Spine has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Aurora Spine's Days Sales Outstanding compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aurora Spine ranks #390 out of 810 companies for Days Sales Outstanding. This puts Aurora Spine in the upper half of its industry. The industry median Days Sales Outstanding is 65.85. Aurora Spine's value of 64.89 is 1.5% below this benchmark. Historically, Aurora Spine's own Days Sales Outstanding has ranged from 49.50 to 94.12 over the past decade. While the company's 10-year median is 68.01 vs. the industry median of 65.85, Aurora Spine has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.85, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aurora Spine's current Days Sales Outstanding of 64.89 is 1.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Aurora Spine and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurora Spine's current Days Sales Outstanding is 64.89, which is near median its own 10-year median of 68.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurora Spine stock overvalued right now?
Based on GuruFocus' analysis, Aurora Spine (ASAPF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.23, compared to a current price of $0.14 — trading 37.5% below its estimated fair value. The current Days Sales Outstanding is 64.89, which is near median its 10-year median of 68.01 and 1.5% below the Medical Devices & Instruments industry median of 65.85. Aurora Spine's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Aurora Spine (ASAPF), the current Days Sales Outstanding is 64.89 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurora Spine (ASAPF) Overvalued in 2026?
Based on GuruFocus' analysis, Aurora Spine stock appears to be undervalued.
The current stock price of $0.14 is trading 37.5% below its estimated GF Value™ of $0.23.
GuruFocus considers Aurora Spine to be Possible Value Trap.
Key valuation signals for ASAPF:
Days Sales Outstanding: 64.89 (near median its 10-year median of 68.01)
GF Value™: $0.23 vs. price of $0.14 (37.5% below fair value)
Industry Position: 1.5% below the Medical Devices & Instruments median (#390 of 810)
No single metric tells the full story. See the ASAPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurora Spine Corp is engaged in the development, manufacture, and sale of minimally invasive, interspinous fusion systems and devices. These 510K and patent protected medical devices improve patient outcomes in the area of spine and sacroiliac joint surgical procedures. The company is focused on bringing new solutions to the spinal implant market through a series of minimally invasive, regenerative spinal implant technologies.
39GF Score
Get the complete analysis for ASAPF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASAPF has been successfully added to your 
